Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 7 months ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
AHA 24: The KRAKEN Trial
Author(s): Stephen Nicholls Added: 7 months ago
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).KRAKEN is a phase 2, randomized, placebo-controlled trial… View more

Prevention & Chronic Conditions
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 3 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
Findings from an Apolipoprotein B-Based Genetic Analysis
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,… View more
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 3 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
AHA 24: The LIBerate-OLE Trial
Author(s): Dean J Kereiakes Added: 7 months ago
AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE … View more

Prevention & Chronic Conditions
AHA 23: The JEWEL-IDE Study
Author(s): John Hummel Added: 1 year ago
AHA 2023 — In this short interview, we are joined by Dr John Hummel (Ohio State University, US) to discuss the findings from the JEWEL-IDE (NCT05201495) study, which investigated the use of the Jewel patch-wearable cardioverter defibrillator (PWCD) system in participants who were at high risk for sudden cardiac arrest. This was a multicenter, prospective, single-arm trial, with 290 participants… View more

Electrophysiology & Arrhythmia
Job title: Director